Improving Lives Through
Innovative Diagnostic Solutions
AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests.
Improving Lives Through
Innovative Diagnostic Solutions
AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests.

COVID-19 &
oncological solutions
AXIM Biotech is in development of a rapid (10-minute) serological diagnostic test that detects SARS-CoV-2 neutralizing antibodies (Nabs) as well as active biomarkers for early detection of cancer

OPHTHALMOLOGICAL DIAGNOSTICS
AXIM has developed and commercialized two point-of-care ophthalmological diagnostic solutions focused on diagnosis of Dry Eye Disease (DED)

DIAGNOSTIC
TEST DEVELOPMENT
Through AXIM’s vertically integrated research and development platform, AXIM is capable of developing diagnostic solutions for a variety of conditions – based on the needs of the client

COVID-19 &
oncological solutions
AXIM Biotech is in development of a rapid (10-minute) serological diagnostic test that detects SARS-CoV-2 neutralizing antibodies (Nabs) as well as active biomarkers for early detection of cancer

OPHTHALMOLOGICAL DIAGNOSTICS
AXIM has developed and commercialized two point-of-care ophthalmological diagnostic solutions focused on diagnosis of Dry Eye Disease (DED)

DIAGNOSTIC
TEST DEVELOPMENT
Through AXIM’s vertically integrated research and development platform, AXIM is capable of developing diagnostic solutions for a variety of conditions – based on the needs of the client
About AXIM
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests. The Company owns two of the only five FDA Cleared Diagnostic tests for Dye Eye Disease.
AXIM® Biotechnologies Signs Exclusive Global Commercialization Agreement With Verséa™ Ophthalmics for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions
SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech” or “AXIM”), an international healthcare solutions company targeting ocular surface diseases, announced today that it has signed an exclusive global commercial...
Optometric Management: Perform a Pre-Fit Ocular Surface Evaluation
The Rapid Quantitative Tear Test for MMP-9 from AXIM Biotechnologies Inc. was featured in a list of DED Diagnostic tools in Optometric Management.com. See the list below: DED Diagnostic Items* BLINK ASSESSMENT iPEDA Blink Analyzer MEIBOMIAN GLAND EXPRESSION Flexx MG...
AXIM Biotechnologies Celebrates Feature on the Vision is More Than 20/20™ Podcast
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, announced today that its CEO John Huemoeller has been...